A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from … DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Arthritis research & therapy 18, 1-12, 2016 | 201 | 2016 |
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid … JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, ... Annals of the Rheumatic Diseases 76 (1), 58-64, 2017 | 194 | 2017 |
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid … JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, ... Annals of the Rheumatic Diseases 76 (1), 58-64, 2017 | 194 | 2017 |
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid … JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, ... Annals of the Rheumatic Diseases 76 (1), 58-64, 2017 | 194 | 2017 |
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with … JS Smolen, JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, ... Annals of the rheumatic diseases 77 (2), 234-240, 2018 | 132 | 2018 |
Phase III Randomized Study of SB 5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis ME Weinblatt, A Baranauskaite, J Niebrzydowski, E Dokoupilova, ... Arthritis & Rheumatology 70 (1), 40-48, 2018 | 132 | 2018 |
Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double‐Blind, phase II trial S Cohen, K Tuckwell, TR Katsumoto, R Zhao, J Galanter, C Lee, J Rae, ... Arthritis & Rheumatology 72 (9), 1435-1446, 2020 | 92 | 2020 |
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results JS Smolen, JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, ... Rheumatology 56 (10), 1771-1779, 2017 | 61 | 2017 |
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial R Westhovens, P Wiland, M Zawadzki, D Ivanova, AB Kasay, ... Rheumatology 60 (5), 2277-2287, 2021 | 43 | 2021 |
OP0068 A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the planetra study DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Annals of the Rheumatic Diseases 72 (Suppl 3), A73-A73, 2013 | 42 | 2013 |
FRI0162 comparable safety and immunogenicity and sustained efficacy after transition to SB2 (An Infliximab Biosimilar) vs ongoing infliximab reference product in patients with … JS Smolen, JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, ... Annals of the Rheumatic Diseases 75 (Suppl 2), 488-488, 2016 | 17* | 2016 |
Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms B Doskaliuk, L Zaiats, R Yatsyshyn, P Gerych, N Cherniuk, O Zimba Rheumatology International 40 (10), 1555-1569, 2020 | 15 | 2020 |
Influence of the complex treatment of hypothyroidism on the leptin level in patients with primary hypothyroidism OM Didushko, PR Herych, IV Cherniavska, RI Yatsyshyn, VI Pankiv Мир медицины и биологии, 59-63, 2018 | 11 | 2018 |
COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis B Doskaliuk, R Yatsyshyn, I Klishch, O Zimba Rheumatology International 41 (12), 2091-2103, 2021 | 9 | 2021 |
Challenges in diagnosis of limited granulomatosis with polyangiitis O Zimba, B Doskaliuk, R Yatsyshyn, M Bahrii, M Hrytsevych Rheumatology international 41 (7), 1337-1345, 2021 | 9 | 2021 |
Rheumatology in Ukraine B Doskaliuk, O Zimba, R Yatsyshyn, V Kovalenko Rheumatology International 40 (2), 175-182, 2020 | 8 | 2020 |
Prostate involvement in granulomatosis with polyangiitis R Yatsyshyn, O Zimba, M Bahrii, B Doskaliuk, V Huryk Rheumatology International 39 (7), 1269-1277, 2019 | 8 | 2019 |
AB0358 phenotypes of secondary sarcopenia in patients with rheumatoid arthritis R Yatsyshyn, I Stoika Annals of the Rheumatic Diseases 77 (Suppl 2), 1351-1351, 2018 | 7 | 2018 |
AB0090 The biochemical basis of animal model of systemic sclerosis B Doskaliuk, L Zaiats, R Yatsyshyn Annals of the Rheumatic Diseases 80 (Suppl 1), 1074-1074, 2021 | 6 | 2021 |
Modern aspects of medical educationin Ukraine R Yatsyshyn, P Gerych, O Didushko Международный эндокринологический журнал 13 (8), 630-631, 2017 | 5 | 2017 |